Hyperfine (NASDAQ:HYPR) COO Thomas Teisseyre Sells 24,188 Shares of Stock

Hyperfine, Inc. (NASDAQ:HYPR) COO Thomas Teisseyre sold 24,188 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $1.21, for a total transaction of $29,267.48. Following the sale, the chief operating officer owned 354,648 shares in the company, valued at approximately $429,124.08. This trade represents a 6.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Hyperfine Price Performance

NASDAQ:HYPR opened at $1.17 on Thursday. The firm’s 50-day moving average price is $1.16 and its 200-day moving average price is $1.20. The company has a market capitalization of $113.69 million, a PE ratio of -2.66 and a beta of 1.09. Hyperfine, Inc. has a 1-year low of $0.53 and a 1-year high of $2.22.

Hyperfine (NASDAQ:HYPR) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. Hyperfine had a negative net margin of 262.29% and a negative return on equity of 95.09%. The company had revenue of $5.29 million during the quarter, compared to analysts’ expectations of $5.30 million. Equities analysts anticipate that Hyperfine, Inc. will post -0.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HYPR has been the subject of several recent research reports. Lake Street Capital lifted their target price on shares of Hyperfine from $2.00 to $2.50 and gave the company a “buy” rating in a report on Thursday, March 19th. Zacks Research upgraded Hyperfine to a “hold” rating in a research note on Thursday, March 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperfine in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Hyperfine has an average rating of “Hold” and a consensus price target of $1.45.

Institutional Trading of Hyperfine

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Hyperfine by 5.7% in the third quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company’s stock worth $5,092,000 after buying an additional 190,136 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Hyperfine by 21.4% during the fourth quarter. Geode Capital Management LLC now owns 815,986 shares of the company’s stock valued at $799,000 after buying an additional 143,975 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Hyperfine during the fourth quarter valued at approximately $212,000. Bridgeway Capital Management LLC increased its position in shares of Hyperfine by 50.2% during the fourth quarter. Bridgeway Capital Management LLC now owns 119,700 shares of the company’s stock valued at $117,000 after acquiring an additional 40,000 shares in the last quarter. Finally, XTX Topco Ltd increased its position in shares of Hyperfine by 47.9% during the fourth quarter. XTX Topco Ltd now owns 80,735 shares of the company’s stock valued at $79,000 after acquiring an additional 26,165 shares in the last quarter. 15.03% of the stock is owned by hedge funds and other institutional investors.

Hyperfine Company Profile

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.